Identification of Drug-Related Problems (DRPs) in Ischemic and Hemorrhagic Stroke Inpatients: A Retrospective Observational Study at a Referral Hospital
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Article Sidebar
Marizah Riska Putri, Erika Lutfia Tunnisaq (2026). Identification of Drug-Related Problems (DRPs) in Ischemic and Hemorrhagic Stroke Inpatients: A Retrospective Observational Study at a Referral Hospital. Journal of Pharmaceutical and Sciences, JPS Volume 9 Nomor 3 (2026). https://doi.org/10.36490/journal-jps.com.v9i3.1825
Main Article Content
Abstract
Stroke remains a leading cause of mortality and long-term disability worldwide, requiring complex pharmacotherapy regimens that significantly increase the risk of Drug-Related Problems (DRPs). This study aimed to identify, categorize, and analyze the prevalence and patterns of DRPs among stroke inpatients using a retrospective observational approach. Data were collected from medical records of 98 hospitalized stroke patients treated between January and December 2025 at a referral hospital. DRPs were classified based on the Pharmaceutical Care Network Europe (PCNE) V9.1 system. The patient cohort comprised 55.1% males and 44.9% females, with 57.1% aged ≥ 60 years. Ischemic stroke accounted for 91.8% of cases, while hemorrhagic stroke constituted 5.1%. Hypertension (69.4%) and Type 2 Diabetes Mellitus (28.6%) were the predominant comorbidities. A total of 135 DRP events were identified in 82 patients (83.7%). The most frequent categories were potential drug–drug interactions (36.3%), untreated indications or need for additional therapy (29.6%), inappropriate drug selection (19.3%), and inappropriate dosing, including absent renal-dose adjustment (14.8%). Critical potential interactions included co-administration of clopidogrel with omeprazole and NSAIDs with antihypertensives. Untreated indications mainly involved the absence of high-intensity statin therapy in ischemic stroke patients. In conclusion, DRPs are highly prevalent among stroke inpatients, particularly driven by polypharmacy and complex comorbidities. Clinical pharmacist interventions are crucial to optimize therapeutic outcomes and minimize adverse drug events
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Feigin VL, Owolabi MO, World Stroke Organization–Lancet Neurology Commission Stroke Collaboration Group. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission. Lancet Neurol. 2023;22:1160–1206. https://doi.org/10.1016/S1474-4422(23)00277-6.
Kementerian Kesehatan Republik Indonesia. Survei Kesehatan Indonesia 2023. Jakarta: Kementerian Kesehatan RI; 2024.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update. Stroke. 2019;50:e344–e418. https://doi.org/10.1161/STR.0000000000000211.
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2021;52:e364–e467. https://doi.org/10.1161/STR.0000000000000375.
Aguiar JP, Dinis-Oliveira RJ, Alves G. Drug-related problems in stroke patients: a systematic review. J Clin Med. 2022;11:4321. https://doi.org/10.3390/jcm11154321.
Pharmaceutical Care Network Europe. PCNE classification for drug-related problems V9.1. Zuidlaren: PCNE Foundation; 2020.
Schindler E, Richling I, Rose O. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm. 2021;43:726–730. https://doi.org/10.1007/s11096-020-01150-w.
Ali M, Shoaib MH, Nesar S, et al. A prospective observational study of estimating drug related problems and clinical outcomes in subtypes of stroke patients. PLoS One. 2024;19:e0295208. https://doi.org/10.1371/journal.pone.0295208.
Andrajati R, Setiadi AP, Saputri FC, et al. Analysis of drug-related problems in ischemic stroke in-patients using the PCNE classification. Pharm Educ. 2024;24:90–98.
Bhusal T, Bhandari S, Subedi S, et al. Study on risk factors and associated drug related problems in hospitalized stroke patients. PLoS One. 2025;20:e0316467. https://doi.org/10.1371/journal.pone.0316467.
Feigin VL, Abate MD, Abate YH, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23:973–1003. https://doi.org/10.1016/S1474-4422(24)00369-7.
Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 guideline for the primary prevention of stroke. Stroke. 2024;55:e344–e424. https://doi.org/10.1161/STR.0000000000000475.
Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization: global stroke fact sheet 2025. Int J Stroke. 2025;20:132–144. https://doi.org/10.1177/17474930241308142.
Ha SH, Kim BJ. Dyslipidemia treatment and cerebrovascular disease: evidence regarding the mechanism of stroke. J Lipid Atheroscler. 2024;13:139–152. https://doi.org/10.12997/jla.2024.13.2.139.
Abukhalil AD, Shatat SS, Abushehadeh RR, et al. Prevalence and safety of prescribing proton pump inhibitors with clopidogrel in Palestine. Biomed Res Int. 2023;2023:3404960. https://doi.org/10.1155/2023/3404960.
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201–211. https://doi.org/10.1007/s40264-014-0144-0.
Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112:959–967. https://doi.org/10.1002/cpt.2526.
Klomjit N, Ungprasert P. Acute kidney injury associated with non-steroidal anti-inflammatory drugs. Eur J Intern Med. 2022;101:21–28. https://doi.org/10.1016/j.ejim.2022.05.003.
Wan EYF, Yu EYT, Chan L, et al. Comparative risks of nonsteroidal anti-inflammatory drugs on CKD. Clin J Am Soc Nephrol. 2021;16:898–907. https://doi.org/10.2215/CJN.18501120.
Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382:9–19. https://doi.org/10.1056/NEJMoa1910355.
American Diabetes Association Professional Practice Committee. Diabetes care in the hospital: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S321–S334. https://doi.org/10.2337/dc25-S016.
Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380:349–357. https://doi.org/10.1016/S0140-6736(12)60813-7.
Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016;25:1984–1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010.
Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116:899–917. https://doi.org/10.14309/ajg.0000000000001245.
Zhang S, Li H, Liu J, et al. Drug-related problems in hospitalized patients with chronic kidney disease: a prospective observational study. Int J Clin Pharm. 2024;46:254–264. https://doi.org/10.1007/s11096-023-01665-8.
Pehlivanli A, Ozturk S, Bektay MY, et al. Impact of a multidisciplinary approach involving clinical pharmacist on resolving drug-related problems in chronic kidney patients: a randomized controlled trial. BMC Nephrol. 2023;24:160. https://doi.org/10.1186/s12882-023-03209-0.
Cengiz KN, Akyol AD, Akalın Ş. The effect of clinical pharmacist-led pharmaceutical care on medication adherence, quality of life and clinical outcomes in patients with stroke. Int J Clin Pharm. 2025;47:402–412. https://doi.org/10.1007/s11096-024-01812-9.